Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects
Strong evidence · 2 studies
Many included trials were from the 1980s-1990s and used outdated comparator drugs (neuroleptics rather than modern anti-emetics like ondansetron). Some individual trials had small samples. The increas
Phase II crossover trial found oral THC:CBD capsules nearly doubled complete response for refractory chemo nausea (25% vs 14%), with 83% of patients preferring cannabis to placebo despite more side effects
Strong evidence · 1 studies
Small phase II sample. Self-titrated dosing introduces variability. The 31% rate of moderate-severe side effects (sedation, dizziness, disorientation) is significant and may limit practical use.
Where questions remain
In a landmark NEJM trial, oral THC prevented chemotherapy vomiting in 80% of completed courses versus 0% for placebo, with no vomiting during subjective highs
Moderate evidence · 37 studies
Small sample of 22 patients with only 20 evaluable. The abstract does not specify the THC dose. Crossover design means carryover effects are possible. Published in 1975, before modern antiemetic drugs
A 1981 critical review found THC showed promise against chemotherapy nausea but identified significant gaps in safety and pharmacological knowledge
Moderate evidence · 37 studies
The review itself acknowledged that the evidence base had significant deficiencies. As a review from 1981, it predates decades of subsequent antiemetic research including modern serotonin antagonists
In 214 cancer patients, THC and prochlorperazine were equally effective against chemotherapy nausea
Moderate evidence · 37 studies
Crossover design means each patient received both treatments, which may introduce carryover effects. The "unblinding" finding suggests the double-blind was not perfect, potentially biasing results. Th
A 1983 review found THC outperformed placebo and standard drugs for chemotherapy nausea, with effectiveness linked to the "high
Moderate evidence · 37 studies
Narrative review format means no systematic quality assessment of included studies. The correlation between "high" and efficacy could reflect unblinding rather than a true mechanistic link.
Research gaps
- Only 10 randomized controlled trials exist out of 242 studies — most evidence is observational or from reviews.
- Sex-specific differences in this area remain understudied.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Meta-Analysis of 30 Trials Found Cannabinoids More Effective Than Standard Anti-Nausea Drugs for Chemotherapy
This was one of the most comprehensive meta-analyses of cannabinoids for chemotherapy nausea at the time. The clear superiority over neuroleptic anti-emetics and overwhelming patient preference provided strong evidence for cannabinoids in this indication.
Large-scale analysis found scientific support for medical cannabis in cancer treatment far outweighs opposition
Cannabis remains Schedule I in the US, complicating cancer research, yet this analysis suggests overwhelming scientific consensus already supports its therapeutic role in oncology.
Cannabinoids prevented chemo nausea better than placebo but have not been tested against modern treatments
Despite decades of interest, almost all evidence predates modern antiemetic protocols, leaving a critical gap for current oncology practice.
Meta-Analysis Finds Cannabis Use Associated with Lower Oral Cancer Risk
Given that cannabis smoke contains many of the same carcinogens as tobacco smoke, a protective association with oral cancer is counterintuitive and demands further investigation into potential anti-tumor mechanisms.
Medicinal cannabis did not improve depression or anxiety in cancer patients but did help appetite
Many cancer patients use cannabis hoping it will help their mental health. This meta-analysis shows that while cannabis may benefit appetite, it does not appear to help with depression, anxiety, or stress in cancer, and higher THC doses may actually worsen anxiety.
Oral THC/CBD capsules improved chemo nausea when standard anti-nausea drugs failed
This is one of the first rigorous trials of standardized oral THC:CBD for refractory chemotherapy nausea, a significant unmet need since many patients fail standard antiemetics.
How the research developed
Pre-2000
14 studies published. Includes 3 RCTs.
2000–2009
15 studies published. Includes 1 meta-analyses, 2 strong-evidence studies.
2010–2014
7 studies published. Includes 1 RCTs.
2015–2019
40 studies published. Includes 2 strong-evidence studies.
2020–present
166 studies published. Includes 4 meta-analyses, 6 RCTs, 9 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 242 peer-reviewed studies: 5 meta-analyses (2%), 10 randomized controlled trials (4%), 52 observational studies (21%), 95 reviews (39%), 6 case studies (2%), 74 other study types (31%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.